Navigation Links
InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
Date:11/8/2007

LOS ALTOS, Calif., Nov. 8 /PRNewswire/ -- InteKrin Therapeutics, Inc., a privately-held clinical stage biopharmaceutical company focused on the development and commercialization of novel drugs for the treatment of diabetes and cardio-metabolic diseases, announced today that Alex M. DePaoli M.D. has joined the company as Chief Medical Officer. Dr. DePaoli will be a member of InteKrin's senior management team and will be responsible for the clinical development of the Company's pipeline of products.

"We are extremely pleased to have a seasoned world-class drug developer of Alex's caliber join the company," said Denny Lanfear, InteKrin Chief Executive. "Alex joins us as we prepare to initiate the Phase IIb study for our lead compound INT131, a non-TZD selective PPAR-gamma modulator (SPPARM) licensed from Amgen earlier this year. While at Amgen, Alex was broadly responsible for the metabolic and endocrine therapeutic area and has been closely involved with multiple novel treatment strategies. His decision to join InteKrin and direct INT131's further development is a strong endorsement of his confidence in its therapeutic potential. The addition of such a highly regarded drug developer and clinician to the team is very positive for the Company."

"I am thrilled to be joining the team at InteKrin and to have the opportunity to advance INT131 into Phase IIb in early 2008," said Dr. DePaoli. "This moiety is the result of a 10-year comprehensive scientific program at Tularik and Amgen resulting in what could be a significant clinical advancement in the treatment of Type 2 Diabetes. Insulin resistance is the key etiological feature to the onset and subsequent progression of the disease and as a true SPPARM, INT131 promises insulin sensitization benefits without the edema, fluid retention and weight gain exhibited by the TZDs."

Dr. DePaoli joins InteKrin after more than 16 years of experience in the diabetes and obesity field. He trained in Clinical and
'/>"/>

SOURCE InteKrin Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
2. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
3. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
4. Cell Therapeutics, Inc. (CTI) CIBC and Rodman & Renshaw Healthcare Conference Presentations to be Webcast
5. Cell Therapeutics, Inc. (CTI) to Report Third Quarter Financial Results on November 8
6. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results
7. Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
8. WorldHeart Appoints David Pellone Chief Financial Officer
9. Novo Nordisk Appoints New Leader of North American Business
10. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
11. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Santiago, Chile (PRWEB) June 20, 2013 ... Chile Montaña has put together their winter season ... of outdoor adventure day trips in and around Santiago ... lead trips into Chile's Central Andes for backcountry skiing, ... , For those who have always dreamed of ...
(Date:6/19/2013)... (PRWEB) June 20, 2013 Everyone is looking for ... and inexpensive way to do so. It is called Skin ... - only 5 minutes per day - to improve health and ... improves general health. How? , Skin Brushing improves general health ... it aids the lymphatic system to drain toxins , ...
(Date:6/19/2013)... CA (PRWEB) June 19, 2013 Paleo Burn ... thousands of people finally sculpt the body they desire with ... other fat loss programs and health food products, Ken Smith ... and finally give consumers an easy, automatic, and permanent solution ... all the details . , After a quick review of ...
(Date:6/19/2013)... Brand new Hypertrophy Max bonus just released by Vince Del Monte ... Max program. Vince and Ben are only making this bonus ... must act quickly. , What is the all new Hypertrophy Max ... 12 month all access pass to the Live Large TV program ... TV is a Monday night show where over 4,000 members from ...
(Date:6/19/2013)... Shreya Rangarajan of Roland Park Country ... on the future of medicine. , Today, Brandeis ... Summit on the Future of Medicine and has selected ... the state of Maryland at the Summit. , "The ... an environment hard to imagine just a few years ...
Breaking Medicine News(10 mins):Health News:Chile Montaña Announces Winter Season Santiago Day Trips 2Health News:Chile Montaña Announces Winter Season Santiago Day Trips 3Health News:A Fast and Fun Way to Better Skin Quality and Overall Health, says Sublime Beauty® 2Health News:Paleo Burn Review Released by TotalWellnessCleanse.net 2Health News:New Hypertrophy Max Bonus Just Released and Only Available for 24 Hours 2Health News:Global Youth Summit on The Future of Medicine-Shreya Rangarajan selected to represent Roland Park Country School and The State of Maryland 2Health News:Global Youth Summit on The Future of Medicine-Shreya Rangarajan selected to represent Roland Park Country School and The State of Maryland 3
... wonder fish medicine for asthma patients began here Thursday amid ... of people were seen standing in queues for their turn ... offering by Bathini Goud family to avoid any controversy. ... cure for asthma, began at 3.42 p.m., the time fixed ...
... Intel has decided to extend its innovation beyond manufacturing ... to team up with other medical and healthcare companies’ ... and seven others have joined hands to enable high-end ... Health Alliance, led by Intel will seek to effectively ...
... longest working hours in Europe - a reason that is ... study //. ,Stress expert Cary Cooper, of Lancaster University, ... their negative effect on men's health, particularly those working in ... of the Daily Mail. ,Researchers studied 2,200 men ...
... be now treated by a new approach involving release ... with mice by scientists // at John Hopkins Institute ... Medicine. ,The discovery by researchers in Hopkins' ... Genetic Medicine reveals that a protein called GCN5 is ...
... common BP medication during first trimester of pregnancy have ... The Food and Drug Administration reports from data collected ... ,The study, led by William Cooper, M.D., M.P.H., associate ... Hospital at Vanderbilt, found infants born to mothers who ...
... Rajasthan man who has pledged not to marry till he passes ... a wife. He has failed in the examination yet again! // ... Behror town, over 140 km from here, has been taking the ... years of his life, he vowed to marry only after getting ...
Cached Medicine News:Health News:Administration of Fish Drug for Asthma Patients Begins in Andhra 2Health News:Diabetes - New Treatment Approach At John Hopkins 2Health News:Birth Defects Link With ACE Inhibitor Use, FDA Reports 2
(Date:6/19/2013)... Pharmacyclics, Inc. (the "Company") (Nasdaq: ... Journal of Medicine ( NEJM ) published results ... Bruton,s tyrosine kinase (BTK) inhibitor ibrutinib in patients with ... ibrutinib may be effective and generally well-tolerated in patients ... separate study examining the safety and efficacy of ibrutinib ...
(Date:6/19/2013)... BRAINTREE, Mass. , June 19, 2013 /PRNewswire/ ... announced several important developments in the pursuit of ... (Logo: http://photos.prnewswire.com/prnh/20120206/NE47232LOGO ) , ... SANM ) for the future production of medical ... , Massachusetts. Sanmina is a leading global provider of ...
(Date:6/19/2013)... 2013 /PRNewswire-iReach/ -- Robert M. Bernstein, M.D., ... procedures and founder of Bernstein Medical – Center ... Doctors, issue of New York Magazine for the ... ) Dr. Bernstein earned his ... reputation as world-renowned hair restoration physician, through a ...
Breaking Medicine Technology:Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 2Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 3Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 4Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 5Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 6Haemonetics Announces Next Steps in Manufacturing Transformation 2Haemonetics Announces Next Steps in Manufacturing Transformation 3Haemonetics Announces Next Steps in Manufacturing Transformation 4Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year 2Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year 3
... 27 Kinex Pharmaceuticals will present results from a Phase ... Meeting in Orlando, on May 29, 2009. The study ... (RPCI) and Fox Chase Cancer Center. Dr. Alex Adjei, ... "Results of a phase I trial of KX2-391, a novel ...
... Administered in Dual Cord Blood Transplant for Hematologic MalignancyLA JOLLA, ... announced today that the first patient has been treated ... molecule Stem Cell Modulator (SCM) designed to increase hematopoietic stem ... pathways that guide cell fate. The study, which is ...
Cached Medicine Technology:Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 2Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 3Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 4
Intended for the quantitative determination of magnesium in serum or plasma. Reaction: Endpoint. Wavelength: 520 nm. Linearity: 6.0 mg/dL (2.5 mmol/L)....
For the quantitative determination of Magnesium in serum. Linearity: 4.0 mEq/L. Working Reagent prepared by simple 1:10 dilution....
For the quantitative determination of total glucose in serum....
Glucose reagent is used for the quantitative determination of glucose in human serum....
Medicine Products: